SEARCH

SEARCH BY CITATION

References

  • 1
    Wienbeck M & Barnert J. Epidemiology of reflux disease and reflux oesophagitis. Scand J Gastroenterol 1989; 24: 713.
  • 2
    Moore RA & Phillips C. Reflux oesophagitis: quantitative systematic review of the evidence of effectiveness of proton pump inhibitors and histamine antagonists. Bandolier 1999; www.jr2.ox.ac.uk/bandolier/bandopubs/gordf/gord.html
  • 3
    Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798810.
  • 4
    Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 5967.
  • 5
    Lind T, Rydberg L, Kylebäck A, et al.Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 8617.
  • 6
    Junghard O, Hassan-Alin M, Hasselgren G. The effect of AUC and Cmax of esomeprazole on acid secretion and intragastric pH. Gastroenterology 2000; 118: A64A64(Abstract).
  • 7
    Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther 2001; 15: 22731.
  • 8
    Jadad A, Moore RA, Carroll D, et al.Assessing the quality of reports of randomised controlled trials: is blinding necessary? Control Clin Trials 1996; 17: 112.DOI: 10.1016/0197-2456(95)00134-4
  • 9
    Mantel N & Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 71948.
  • 10
    DerSimonian R & Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 17788.
  • 11
    Review Manager (RevMan) [Computer program] Version 4.1 for Windows. Oxford, UK: The Cochrane Collaboration, 2000: CD-ROM and Internet.
  • 12
    AstraZeneca. Study B2 and Supplementary Information for Kahrilas et al. (ref. 14) Data on file (NEX/056/FEB2001).
  • 13
    Richter JE, Kahrilas PJ, Johanson J, et al.Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 65665.
    Direct Link:
  • 14
    Kahrilas PJ, Falk GW, Johnson DA, et al.Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 337: 124958.
  • 15
    Dekkers CPM, Beker JA, Thjodleifsson B, et al.Double blind, placebo controlled comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of ersoive or ulcerative GORD. Aliment Pharmacol Ther 1999; 13: 4957.DOI: 10.1046/j.1365-2036.1999.00438.x
  • 16
    Delchier J, Cohen G, Humphries TJ. Rabeprazole is comparable to omeprazole in the healing of erosive GERD and provides more rapid heartburn relief. Gastroenterology 1999; 116: A146A146(Abstract).
  • 17
    Hatlebakk JG, Berstad A, Carling L, et al.Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Scan J Gastroenterol 1999; 28: 2248.
  • 18
    Vcev A, Stimac D, Vceva A, et al.Pantoprazole versus omeprazole in the treatment of reflux esophagitis. Acta Med Croat 1999; 53: 7982.
  • 19
    Pilotto A, Franceschi M, Leandro G, et al.Comparison of omeprazole, lansoprazole and pantoprazole in the treatment of elderly patients with esophagitis. Ital J Gastroenterol Hepatol 1998; 30(Suppl. 2): 142142(Abstract).
  • 20
    Vicari F, Belin J, Marek L. Pantoprazole 40 mg versus omeprazole 20 mg in the treatment of reflux esophagitis. Gastroenterology 1998; 114: A324A324(Abstract).
  • 21
    Vcev A, Stimac D, Vceva A, et al.Lansoprazole versus omeprazole in the treatment of reflux oesophagitis. Acta Med Croat 1997; 51: 1714.
  • 22
    Castell DO, Richter JE, Robinson M. Efficacy and safety of lansoprazole in the treatment of reflux oesophagitis. Am J Gastroenterol 1996; 91: 174957.
  • 23
    Cordova-Villalobas JA, Ramirez-Barba EJ, Ramirez-Covarrubias JC. Reflux oesophagitis: a comparative study of lansoprazole and omeprazole as short-term therapy. Rev Gastroenterol Mex 1996; 61: 3069.
  • 24
    Hotz J, Gangl A, Heinzerling H. Pantoprazole versus omeprazole in acute reflux esophagitis. Gastroenterology 1996; 110: A136A136(Abstract).
  • 25
    Mee AS & Rowley JL, Lansoprazole Clinical Research Group. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996; 10: 75763.
  • 26
    Corinaldesi R, Valentini M, Belaiche J, et al.Pantoprazole and omeprazole in the treatment of reflux esophagitis. Aliment Pharmacol Ther 1995; 9: 66771.
  • 27
    Mossner J, Holscher AH, Herz R, Schneider A. A double blind study of pantoprazole and omeprazole in the treatment of reflux esophagitis. Aliment Pharmacol Ther 1995; 9: 3216.
  • 28
    Petite JP, Group Multicentrique. Efficacté compareé du lansoprazole et de l’oméprazole dans le traitement de l’oesophagite peptique. Med Chir Dig 1995; 24: 2914.
  • 29
    Corallo J, Vicari F, Forestier S, Joubert M. Lansoprazole in the acute treatment of reflux esophagitis. Gastroenterology 1993; 104: A58A58(Abstract).
  • 30
    Pearson K. On a criterion that a given system of deviations from the probable in the case of a correlated system of variable is such that it can reasonably be supposed to have arisen in random sampling. Philosophical Magazine 1900; 50: 15775.
  • 31
    Lind T, Cederberg C, Ekenved G, et al.Effect of omeprazole – a gastric proton pump inhibitor – on pentagastrin stimulated acid secretion in man. Gut 1983; 24: 2706.
  • 32
    Fass R, Murthy U, Hayden CW, et al.Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy – a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14: 1595603.
  • 33
    Kahrilas PJ. Strategies for medical management of reflux disease. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 77591.
  • 34
    Goeree R, O'Brien B, Hunt R, et al.Economic evaluation of long-term management strategies for erosive oesophagitis. Pharmacoeconomics 1999; 16: 67997.
  • 35
    Röhss K, Wilder-Smith C, Claar-Nilsson C, et al.Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitors. Gastroenterology 2001; 120: A419A419(Abstract).